No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Cyramza (ramucirumab) is a monoclonal antibody drug used to treat certain types of lung cancer. It is used in combination with other drugs to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Cyramza works by blocking the activity of a protein called vascular endothelial growth factor (VEGF), which helps cancer cells grow and spread. Cyramza is approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC in combination with other drugs.
The Cyramza market is a rapidly growing segment of the global lung cancer drugs market. It is expected to witness strong growth in the coming years due to the increasing prevalence of lung cancer and the growing demand for effective treatments. The market is also driven by the increasing number of clinical trials and the availability of new drugs.
Some of the key players in the Cyramza market include Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, Pfizer Inc., and Bristol-Myers Squibb Company. Show Less Read more
